Loading
Rockwell Medical, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Irrevocable Larson Family Investment Trust, was filed 15 Apr 2025.
Rockwell Medical, Inc.: what insiders have been doing
Headquartered in United States, United States, Rockwell Medical, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 1995. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 22 October 2026, brought 21 filings signed by 11 insiders.
No insider bought on the market over the period, while 4 insiders filed 4 sales totalling €14k. At €7,427, the sale published on 5 October 2026 by Strobeck Mark is the largest of the period (0.024% of market cap).
With 21 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Over the whole record (from 2016), the tally stands at 75 purchases and 53 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 69.3 m USD and net income at -5.3 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 5 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
260
Thresholds
n/a
Buy Volume
€935,285
75 ops. · all time
Sell Volume
€1M
53 ops. · all time
Who traded when
BuySaleIrrevocable Larson Family Investment Trust21 buys
Mark Strobeck5 sales
Jesse Neri4 sales
Timothy Chole4 sales
Heather Hunter2 sales
Ravich Mark H2 sales
+1 other insider
Since the insiders bought
- -10.7%Entry US$10.30 · Close at T+365 US$9.20
- -56.0%Entry US$210.10 · Close at T+365 US$92.40
- -54.2%Entry US$223.30 · Close at T+365 US$102.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,574 of 26,280 companies
17.6
score / 100
Value18
Quality17
FCF yld-4.2%
Earn yld-19%
EV/EBITDA·
ROE-16%
Gross mgn17%
Net mgn-7.9%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.08
Analyst consensus
2 analysts1.50/5
US$20.00Target US$20.00(+182%)US$20.00
Income statement
RevenueUS$69.3M
Gross profitUS$11.7M17% margin
EBITDA-US$2M-3% margin
Net income-US$5.5M-7.3% margin
Valuation
P/Book0.8x
Beta1.63
Balance sheet & cash
Market capUS$28.5M
Total debtUS$12.5M
Free Cash Flow-US$1.2M
Debt / Equity40%
Profitability & ownership
ROE-15.5%
ROA-5.2%
% insiders14.8%
% institutions8.5%
Last declaration on 5 October 2026
Declarations260 total
1,000 shares@ US$8.420.024% mcap10.6% of flowCommon StockSEC:0001628280-26-064902:0
1,000 shares@ US$8.400.024% mcap11.8% of flowCommonSEC144:0001974078-26-000373
9,633 shares0Common StockSEC:0001628280-26-047119:0
15,000 shares0Common StockSEC:0001628280-26-047117:0
9,633 shares0Common StockSEC:0001628280-26-047127:0
15,000 shares0Common StockSEC:0001628280-26-047108:0
9,633 shares0Common StockSEC:0001628280-26-047126:0
30,000 shares0Common StockSEC:0001628280-26-047107:0
15,000 shares0Common StockSEC:0001628280-26-047110:0
9,633 shares0Common StockSEC:0001628280-26-047125:0
9,633 shares0Common StockSEC:0001628280-26-047121:0
15,000 shares0Common StockSEC:0001628280-26-047114:0
2,444 shares@ US$0.9027.8% of flowCommon StockSEC:0001628280-26-018320:0
3,667 shares@ US$0.9022.7% of flowCommon StockSEC:0001628280-26-018319:0
2,444 shares@ US$0.9021.7% of flowCommon StockSEC:0001628280-26-018317:0
7,333 shares@ US$0.9010.4% of flowCommon StockSEC:0001628280-26-018314:0
2,444 shares@ US$0.9010.1% of flowCommon StockSEC:0001628280-26-018315:0
2,868 shares@ US$0.835529.7% of flowCommon StockSEC:0001628280-26-000435:0
886 shares@ US$0.83557.2% of flowCommon StockSEC:0001628280-26-000424:0
25,000 shares0Common StockSEC:0001104659-25-114698:0
5,079 shares@ US$0.87100.0% of flowCommon StockSEC:0001628280-25-052908:0
2,868 shares@ US$1.1942.4% of flowCommon StockSEC:0001104659-25-098020:0
6,926 shares@ US$1.1912.7% of flowCommon StockSEC:0001628280-25-043430:0
2,868 shares@ US$1.1915.5% of flowCommon StockSEC:0001628280-25-043434:0
886 shares@ US$1.1910.2% of flowCommon StockSEC:0001628280-25-043432:0
25 of 260 declarations
About Rockwell Medical, Inc.
Rockwell Medical, Inc. (ticker: RMTI) is a healthcare company listed on the Nasdaq market in the United States (United States), focused on the hemodialysis supply chain. From an equity-investor perspective, the company occupies a specialized but essential niche in renal care: it develops, manufactures, commercializes, and distributes a portfolio of products used by dialysis providers, hospitals, and other care settings treating patients with end-stage kidney disease. Its headquarters are in Wixom, Michigan.
Rockwell’s business is concentrated in a single operating area, hemodialysis, with products and services designed to support treatment across outpatient dialysis centers, hospital-based settings, skilled nursing facilities, and, in some cases, home care environments. The company emphasizes dialysis-related solutions and consumables that are critical to the treatment process. That focus gives Rockwell direct exposure to a structurally supported market, underpinned by chronic kidney disease prevalence and an aging population. At the same time, the company remains dependent on a relatively small number of large customers and contract wins, which makes commercial execution especially important.
Read moreShow less
Historically, Rockwell Medical has been a long-standing U.S. player in renal care, and in recent years management has increasingly emphasized operational discipline, margin improvement, and customer retention. The strategic message has been clear: strengthen long-term customer partnerships, secure appropriate pricing, and improve the company’s path toward sustainable profitability. The business remains primarily U.S.-oriented, although Rockwell states that it serves dialysis providers worldwide through its product portfolio and distribution channels.
Recent developments matter for the investment case. In 2025, Rockwell announced multiple new supply and purchase agreements, including a notable partnership with Innovative Renal Care, one of the largest dialysis service providers in the United States. The company also reported new agreements with university medical centers, kidney centers, and hospital systems, while working to renew and expand existing relationships. In early 2026, management highlighted improved gross margin, tighter expense control, and positive cash-generation trends, signaling that profitability and balance-sheet resilience are central priorities.
For investors, RMTI remains a small-cap, specialized healthcare name with a defensive end market but meaningful execution risk. Its appeal lies in the recurring nature of dialysis demand and the essential character of its products, while its challenges include customer concentration, pricing pressure, and the need to sustain operating improvements over time.
